

Additional file

Table A. Baseline characteristics for participants retained and lost at 6 (T2) and 12 (T3) months.

Variable	Retained T2 (n = 386)	Lost T2 (n = 119)	p-value	Retained T3 (n = 245)	Lost T3 (n = 260)	p-value
Sociodemographic and clinical characteristics						
Age (years), median (P25-P75)	79 (72–84)	81 (73–87)	0.040	79 (74–84)	79 (71–85)	0.468
Sex: females, n (%)	246 (64)	86 (72)	0.086	162 (66)	170 (65)	0.861
Living alone, n (%)	170 (44)	67 (56)	0.049	103 (42)	134 (52)	0.077
Residence, n (%)			0.015			0.160
Apartment	197 (51)	67 (56)		120 (49)	144 (55)	
House	179 (46)	44 (37)		117 (48)	106 (41)	
Other ^a	10 (3)	8 (7)		8 (3)	10 (4)	
Recruitment site, n (%)			0.007			0.002
Norway	182 (47)	55 (46)		106 (43)	131 (50)	
Germany	182 (47)	47 (39)		128 (52)	101 (39)	
France	22 (6)	17 (14)		11 (4)	28 (11)	
Days since surgery, median (P25-P75)	62 (24–140)	48 (13–142)	0.380	58 (20–154)	60 (26–134)	0.512
Recovery phase groups, n (%)			0.052			0.265
Acute	69 (18)	30 (25)		54 (22)	45 (17)	
Post-Acute	91 (24)	27 (23)		56 (23)	62 (24)	
Extended	164 (42)	36 (30)		88 (36)	112 (43)	
Long-Term	62 (16)	26 (22)		47 (19)	41 (16)	
Fracture Type, n (%)			0.257			0.677
FNF ^b	271 (70)	77 (65)		171 (70)	177 (68)	
ECF ^c	115 (30)	42 (35)		74 (30)	83 (32)	
Surgery Type, n (%) ^d			0.787			0.912
FNF Arthroplasty	168 (44)	46 (39)		105 (43)	109 (42)	
FNF Internal fixation	94 (24)	28 (24)		59 (24)	63 (24)	
ECF Arthroplasty	1 (0)	1 (1)		1 (0)	1 (0)	
ECF Internal fixation	113 (29)	41 (34)		73 (30)	81 (31)	
Use of walking aids, n (%)			0.195			0.676
Indoor only	2 (1)	0 (0)		1 (0)	1 (0)	
Outdoor only	38 (10)	11 (9)		24 (10)	25 (10)	
Indoor and outdoor	191 (49)	61 (51)		115 (47)	137 (53)	
No walking aid	86 (22)	17 (14)		51 (21)	52 (20)	
Not applicable ^e	69 (18)	30 (25)		54 (22)	45 (17)	
Type of wearable device, n (%)			0.770			<0.001
AX6	300 (78)	94 (79)		172 (70)	222 (85)	
McRoberts MM+	86 (22)	25 (21)		73 (30)	38 (15)	
Device wear-time (days), mean (SD) ^f	6.76 (0.64)	6.49 (1.03)	0.004	6.71 (0.72)	6.68 (0.80)	0.837
Clinical and patient-reported outcomes						
6MinWT ^g distance (m), mean (SD)	295 (126)	239 (116)	<0.001	286 (126)	281 (126)	0.611
SPPB ^h total score [0-12], median (P25-P75)	6 (4–9)	4 (3–7)	<0.001	6 (4–9)	6 (4–8)	0.393

Gait speed (4MWT ^l) (m/s), mean (SD)	0.71 (0.34)	0.59 (0.36)	<0.001	0.70 (0.36)	0.66 (0.34)	0.225
TUG ^j (s), median (P25-P75)	16 (11–23)	21 (14–29)	0.001	17 (11–24)	17 (12–24)	0.447
LLFDI-FC ^k [0–100], median (P25–P75)	51 (44–60)	48 (41–55)	0.018	50 (43–60)	50 (43–60)	0.802
WB step count (number per day) ^l , median (P25–P75)	2216 (925–4740)	1590 (540–3066)	0.013	1909 (855–4724)	2226 (748–4150)	0.865
Systolic Blood Pressure (mmHg), mean (SD)	135 (22)	139 (24)	0.079	135 (21)	137 (23)	0.212

Differences between participants retained and lost to follow-up at 6- and 12 months were assessed using the Wilcoxon rank-sum test for continuous variables and the chi-square test or Fischer's exact test, as appropriate, for categorical variables. Two-sided p-values are reported, with p < 0.05 considered statistically significant.

^a This category consisted of participants living in an independent living unit (n=8) or in a temporary residential care facility (n=2).

^b FNF: Femoral neck fracture

^c ECF: Extracapsular fracture

^d Missing surgery type for 9 participants with femoral neck fractures, and for 1 participant with extracapsular fracture.

^e Acute patients were not included in the walking aid analysis as only pre-fracture walking aid usage was assessed.

^f The average device wear-time in days during the 7-day mobility assessment for participants with at least 3 valid days.

^g 6MinWT: 6-minute walk test

^h SPPB: Short Physical Performance Battery

ⁱ 4MWT: 4-meter walk test

^j TUG: Timed-Up and Go test

^k LLFDI-FC: Late Life Function and Disability Instrument – Function Component – total score

^l Weekly mean of daily sum of steps taken within all WBs

Table B. Sociodemographic and clinical characteristics for the subsample* (n=386) at the first visit (T1), stratified by recovery phase groups.

Variable	Acute n = 69 (18%)	Post-Acute n = 91 (24%)	Extended n = 164 (42%)	Long-Term n = 62 (16%)
Age (years), median (P25–P75)	78 (73–84)	81 (73–86)	77 (71–82)	79 (72–84)
Sex: females, n (%)	49 (71)	57 (63)	102 (62)	38 (61)
Living alone, n (%)	31 (45)	46 (51)	65 (40)	28 (45)
Residence, n (%):				
Apartment	32 (46)	44 (48)	95 (58)	26 (42)
House	36 (52)	45 (49)	65 (40)	33 (53)
Others ^a	1 (2)	2 (3)	4 (2)	3 (5)
Recruitment site, n (%):				
Norway	63 (91)	26 (29)	70 (43)	23 (37)
Germany	5 (7)	64 (70)	80 (49)	33 (53)
France	1 (1)	1 (1)	14 (9)	6 (10)
Days since surgery, median (P25–P75)	4 (3–5)	28 (23–35)	98 (65–134)	332 (244–353)
Fracture Type, n (%):				
FNF ^b	62 (90)	60 (66)	106 (65)	43 (69)
ECF ^c	7 (10)	31 (34)	58 (35)	19 (31)
Surgery Type, n (%) ^d				
FNF Arthroplasty	34 (49)	43 (47)	65 (40)	26 (42)
FNF Internal fixation	28 (41)	16 (18)	35 (21)	15 (24)
ECF Arthroplasty	1 (1)	0 (0)	0 (0)	0 (0)
ECF Internal fixation	6 (9)	31 (34)	57 (35)	19 (31)
Use of walking aids, n (%):				
Indoor only	-	0 (0)	1 (1)	1 (2)
Outdoor only	-	2 (2)	24 (15)	12 (19)

Indoor and outdoor	-	83 (91)	89 (54)	19 (31)
No walking aid	-	6 (7)	50 (30)	30 (48)
Not applicable ^e	69 (100)	0 (0)	0 (0)	0 (0)
Type of wearable device, n (%)				
AX6	53 (77)	70 (77)	133 (81)	44 (71)
McRoberts MM+	16 (23)	21 (23)	31 (19)	18 (29)
Device wear-time (days), mean (SD) ^f	6.68 (0.72)	6.79 (0.53)	6.76 (0.71)	6.82 (0.53)

*The subsample includes only participants with clinical and DMO data at T1 and T2. Variables are shown by the recovery phase groups. Recovery phase groups were stratified by the number of days from surgery to first visit: Acute (≤ 14 days), Post-Acute (15-42 days), Extended (43-182 days), Long-Term (183-365 days).

^a This category consisted of participants living in an independent living unit (n=8) or in a temporary residential care facility (n=2).

^b FNF: Femoral neck fracture

^c ECF: Extracapsular fracture

^d Missing surgery type for participants with femoral neck fractures (n = 9), and for participants with extracapsular fractures (n = 1).

^e Acute patients were not included in the walking aid analysis as only pre-fracture walking aid usage was assessed.

^f The average device wear-time in days during the 7-day mobility assessment for participants with at least 3 valid days.

Table C. Clinical- and patient-reported outcomes for the subsample* (n=386) at the first visit (T1), stratified by recovery phase groups.

Variable	Acute n = 69 (18%)	Post-Acute n = 91 (24%)	Extended n = 164 (42%)	Long-Term n = 62 (16%)
6MinWT ^a distance (m), mean (SD)	.. ^b	236 (107)	312 (126)	335 (126)
SPPB ^c total score [0-12], median (P25-P75)	3 (2-5) ^d	5.0 (4-8)	8 (6-10)	9 (6-11)
Gait speed (4MWT ^e) (m/s), mean (SD)	0.37 (0.21)	0.65 (0.22)	0.81 (0.32)	0.92 (0.35)
TUG ^f (s), median (P25-P75)	.. ^b	21 (15-31)	15 (11-19)	12 (10-20)
LLFDI-FC ^g [0-100], median (P25-P75)	.. ^b	44 (40-54)	52 (47-60)	60 (49-70)
WB step count (number per day) ^h , median (P25-P75)	530 (271-1116)	1733 (709-3071)	3206 (1638-5898)	4452 (2178-7328)
Systolic Blood Pressure (mmHg), mean (SD)	134 (23)	133 (18)	135 (22)	140 (22)

*The subsample includes only participants with clinical and DMO data at T1 and T2. The variables are shown by the recovery phase groups. Recovery phase groups were stratified by the number of days from surgery to first visit: Acute (≤ 14 days), Post-Acute (15-42 days), Extended (43-182 days), Long-Term (183-365 days).

^a 6MinWT: 6-minute walk test

^b Not applicable in the acute setting

^c SPPB: Short Physical Performance Battery

^d Due to the recency of the hip fracture surgery, acute patients did not perform the 5 chair-rise test of the SPPB and could therefore achieve a maximum of 8 points instead of 12

^e 4MWT: 4-meter walk test

^f TUG: Timed-Up and Go test

^g LLFDI-FC: Late Life Function and Disability Instrument – Function Component – total score

^h Weekly mean of daily sum of steps taken within all WBs

Table D. Number of participants with a Walking Period at each assessment*, overall and for each recovery phase group.

Walking Period	Assessment	Group	Number of participants having the Walking Period		Number of Walking Periods, Median (P25-P75)
			n	%	
WBs >30s	T1	Total	482	95	44 (14–91)
		Acute	86	87	9 (3–28)
		Post-Acute	115	97	48 (18–84)
		Extended	196	98	61 (22–127)
		Long-Term	85	97	70 (28–123)
	T2	Total	370	96	72 (27–121)
		Acute	68	99	72 (27–103)
		Post-Acute	87	96	60 (17–129)
		Extended	153	93	77 (26–125)
		Long-Term	62	100	65 (40–119)
	T3	Total	231	94	74 (30–112)
		Acute	53	98	85 (46–110)
		Post-Acute	51	91	40 (5–94)
		Extended	83	94	79 (40–140)
		Long-Term	44	94	68 (36–109)
Walking Clusters	T1	Total	421	83	9 (2–17)
		Acute	62	63	2 (0–5)
		Post-Acute	102	86	9 (4–17)
		Extended	177	88	11 (4–20)
		Long-Term	80	91	13 (5–22)
	T2	Total	345	89	13 (5–22)
		Acute	63	91	13 (4–19)
		Post-Acute	78	86	12 (4–24)
		Extended	146	89	14 (5–23)
		Long-Term	58	94	14 (8–21)
	T3	Total	210	86	13 (6–21)
		Acute	52	96	16 (9–23)
		Post-Acute	40	71	8 (0–17)
		Extended	78	89	14 (7–26)
		Long-Term	40	85	11 (8–21)

*Three assessments: The first visit (T1, N = 505), 6-month (T2, n = 386) and 12-month follow-up (T3, n = 245). Recovery phase groups were stratified by the number of days from surgery to first visit: Acute (≤ 14 days), Post-Acute (15–42 days), Extended (43–182 days), Long-Term (183–365 days).

Table E. Sensitivity analyses of the convergent and divergent validity of alternative Walking Period threshold definitions for the full sample (N=505).

Thresholds		Number of participants having the Walking Period		DMO ^a	Distance (m)	Convergent						Divergent	Correlations meeting expectations
WB duration	Inter-Bout duration	n	%	Weekly aggregation	Median (P25– P75)	6MinWT ^{b,c}	SPPB total ^{c,d}	4m gait speed ^e	TUG ^{c,f}	LLFDI-FC ^{c,g}	Step count ^h	Systolic BP ⁱ	
10s	n.a.	504	99.8										
				Mean	15 (11–19)	0.53 (0.45 , 0.60)	0.53 (0.47 , 0.60)	0.57 (0.50 , 0.63)	-0.51 (-0.58, -0.43)	0.48 (0.39, 0.55)	0.65 (0.60 , 0.71)	-0.03 (-0.12, 0.07)	6/7 (86%)
				SD	14 (7–28)	0.61 (0.54 , 0.67)	0.60 (0.54 , 0.66)	0.60 (0.54 , 0.66)	-0.58 (-0.64, -0.50)	0.55 (0.47 , 0.61)	0.71 (0.65 , 0.75)	0.00 (-0.09, 0.09)	7/7 (100%)
				Median	10 (8–11)	0.43 (0.34, 0.51)	0.42 (0.35, 0.50)	0.50 (0.43 , 0.56)	-0.43 (-0.52, -0.35)	0.38 (0.29, 0.47)	0.54 (0.48 , 0.61)	-0.05 (-0.14, 0.04)	3/7 (43%)
				P95	38 (24–55)	0.44 (0.36, 0.52)	0.46 (0.39, 0.52)	0.49 (0.41, 0.55)	-0.41 (-0.49, -0.32)	0.41 (0.32, 0.48)	0.58 (0.51 , 0.64)	-0.01 (-0.10, 0.08)	2/7 (29%)
10s	<60s	498	98.6										
				Mean	35 (23–54)	0.42 (0.34, 0.49)	0.39 (0.31, 0.46)	0.42 (0.34, 0.49)	-0.40 (-0.48, -0.31)	0.39 (0.30, 0.47)	0.54 (0.47 , 0.61)	-0.00 (-0.09, 0.09)	2/7 (29%)
				SD	41 (21–96)	0.55 (0.47 , 0.61)	0.54 (0.47 , 0.60)	0.54 (0.47 , 0.60)	-0.53 (-0.60, -0.45)	0.51 (0.43 , 0.58)	0.69 (0.63 , 0.73)	0.02 (-0.07, 0.11)	7/7 (100%)
				Median	18 (12–24)	0.12 (0.01, 0.22)	0.06 (-0.03, 0.15)	0.15 (0.06, 0.24)	-0.10 (-0.20, 0.00)	0.07 (-0.04, 0.17)	0.22 (0.13, 0.30)	-0.09 (-0.17, 0.00)	1/7 (14%)

				P95	107 (60–203)	0.40 (0.32, 0.48)	0.42 (0.35, 0.49)	0.44 (0.36, 0.51)	-0.39 (-0.47, -0.30)	0.40 (0.31, 0.47)	0.57 (0.51, 0.63)	0.03 (-0.07, 0.12)	2/7 (29%)
10s	<5min	502	99.4										
				Mean	64 (35–123)	0.59 (0.51, 0.65)	0.50 (0.43, 0.57)	0.52 (0.45, 0.59)	-0.55 (-0.63, -0.47)	0.53 (0.45, 0.60)	0.70 (0.64, 0.75)	0.01 (-0.08, 0.10)	7/7 (100%)
				SD	96 (40–211)	0.68 (0.62, 0.73)	0.61 (0.54, 0.66)	0.60 (0.53, 0.66)	-0.65 (-0.70, -0.58)	0.64 (0.58, 0.70)	0.77 (0.73, 0.81)	0.03 (-0.06, 0.12)	7/7 (100%)
				Median	28 (16–46)	0.27 (0.17, 0.37)	0.23 (0.14, 0.32)	0.32 (0.23, 0.40)	-0.27 (-0.37, -0.17)	0.22 (0.12, 0.32)	0.42 (0.34, 0.49)	-0.05 (-0.14, 0.04)	1/7 (14%)
				P95	236 (110–513)	0.63 (0.56, 0.68)	0.57 (0.50, 0.63)	0.57 (0.50, 0.63)	-0.58 (-0.65, -0.51)	0.59 (0.52, 0.65)	0.74 (0.68, 0.78)	0.03 (-0.06, 0.13)	7/7 (100%)
10s	<10min	502	99.4										
				Mean	64 (35–123)	0.59 (0.51, 0.65)	0.50 (0.43, 0.57)	0.52 (0.44, 0.59)	-0.55 (-0.62, -0.48)	0.53 (0.45, 0.60)	0.70 (0.64, 0.75)	0.01 (-0.09, 0.10)	7/7 (100%)
				SD	96 (40–211)	0.68 (0.62, 0.73)	0.61 (0.54, 0.67)	0.60 (0.53, 0.66)	-0.65 (-0.70, -0.58)	0.64 (0.58, 0.70)	0.77 (0.73, 0.81)	0.03 (-0.06, 0.12)	7/7 (100%)
				Median	28 (16–46)	0.27 (0.17, 0.37)	0.23 (0.15, 0.32)	0.32 (0.23, 0.40)	-0.27 (-0.37, -0.17)	0.22 (0.12, 0.32)	0.42 (0.33, 0.49)	-0.05 (-0.14, 0.04)	1/7 (14%)
				P95	236 (110–513)	0.63 (0.56, 0.68)	0.57 (0.50, 0.63)	0.57 (0.50, 0.63)	-0.58 (-0.65, -0.51)	0.59 (0.52, 0.65)	0.74 (0.69, 0.78)	0.03 (-0.06, 0.13)	7/7 (100%)
30s	n.a.	482	95.5										
				Mean	39 (28–56)	0.66 (0.59, 0.72)	0.64 (0.58, 0.70)	0.63 (0.57, 0.69)	-0.64 (-0.70, -0.58)	0.61 (0.54, 0.67)	0.72 (0.67, 0.77)	0.05 (-0.05, 0.14)	7/7 (100%)

				SD	23 (10–55)	0.65 (0.59, 0.71)	0.64 (0.58, 0.69)	0.62 (0.56, 0.67)	-0.64 (-0.69, -0.57)	0.61 (0.54, 0.67)	0.74 (0.69, 0.79)	0.04 (-0.05, 0.13)	7/7 (100%)
				Median	31 (25–38)	0.58 (0.50, 0.64)	0.57 (0.50, 0.63)	0.58 (0.51, 0.64)	-0.57 (-0.63, -0.49)	0.51 (0.43, 0.58)	0.64 (0.58, 0.70)	0.07 (-0.02, 0.17)	7/7 (100%)
				P95	80 (47–160)	0.63 (0.57, 0.69)	0.63 (0.58, 0.69)	0.61 (0.54, 0.66)	-0.63 (-0.68, -0.56)	0.60 (0.54, 0.66)	0.74 (0.69, 0.78)	0.04 (-0.06, 0.13)	7/7 (100%)
30s	<60s	421	83.4										
				Mean	148 (85–276)	0.55 (0.47, 0.63)	0.55 (0.48, 0.62)	0.51 (0.43, 0.58)	-0.54 (-0.61, -0.46)	0.53 (0.45, 0.61)	0.66 (0.61, 0.72)	0.03 (-0.07, 0.13)	7/7 (100%)
				SD	100 (28–285)	0.60 (0.52, 0.67)	0.59 (0.53, 0.66)	0.55 (0.48, 0.62)	-0.58 (-0.65, -0.51)	0.56 (0.48, 0.63)	0.73 (0.69, 0.78)	-0.00 (-0.10, 0.09)	7/7 (100%)
				Median	103 (68–157)	0.38 (0.28, 0.47)	0.41 (0.32, 0.48)	0.37 (0.28, 0.45)	-0.38 (-0.47, -0.28)	0.40 (0.31, 0.48)	0.49 (0.41, 0.56)	0.07 (-0.02, 0.17)	1/7 (14%)
				P95	334 (138–828)	0.60 (0.52, 0.66)	0.60 (0.53, 0.66)	0.56 (0.49, 0.62)	-0.58 (-0.64, -0.51)	0.56 (0.48, 0.63)	0.73 (0.69, 0.77)	0.01 (-0.09, 0.11)	7/7 (100%)
30s	<5min	446	88.3										
				Mean	239 (129–463)	0.57 (0.50, 0.64)	0.54 (0.47, 0.61)	0.51 (0.43, 0.58)	-0.55 (-0.62, -0.47)	0.56 (0.48, 0.62)	0.69 (0.63, 0.74)	0.07 (-0.03, 0.16)	7/7 (100%)
				SD	194 (72–469)	0.62 (0.55, 0.68)	0.59 (0.53, 0.65)	0.56 (0.50, 0.63)	-0.59 (-0.65, -0.52)	0.58 (0.50, 0.64)	0.76 (0.72, 0.80)	0.03 (-0.07, 0.12)	7/7 (100%)
				Median	150 (95–251)	0.43 (0.34, 0.51)	0.41 (0.33, 0.48)	0.38 (0.30, 0.46)	-0.42 (-0.51, -0.33)	0.43 (0.34, 0.51)	0.53 (0.45, 0.59)	0.10 (0.01, 0.19)	2/7 (29%)

				P95	609 (255–1445)	0.62 (0.55, 0.68)	0.60 (0.54, 0.66)	0.57 (0.50, 0.64)	-0.59 (-0.65, -0.52)	0.59 (0.52, 0.65)	0.77 (0.72, 0.80)	0.04 (-0.06, 0.14)	7/7 (100%)
30s	<10min	446	88.3										
				Mean	239 (129–463)	0.57 (0.49, 0.64)	0.54 (0.47, 0.60)	0.51 (0.43, 0.58)	-0.55 (-0.62, -0.47)	0.56 (0.48, 0.62)	0.69 (0.63, 0.74)	0.07 (-0.03, 0.16)	7/7 (100%)
				SD	194 (72–469)	0.62 (0.55, 0.68)	0.59 (0.53, 0.65)	0.56 (0.49, 0.63)	-0.59 (-0.65, -0.52)	0.58 (0.51, 0.64)	0.76 (0.71, 0.80)	0.03 (-0.07, 0.13)	7/7 (100%)
				Median	150 (95–251)	0.43 (0.34, 0.51)	0.41 (0.33, 0.48)	0.38 (0.30, 0.46)	-0.42 (-0.50, -0.33)	0.43 (0.34, 0.51)	0.53 (0.45, 0.59)	0.10 (0.00, 0.19)	2/7 (29%)
				P95	609 (255–1445)	0.62 (0.55, 0.68)	0.60 (0.54, 0.66)	0.57 (0.51, 0.64)	-0.59 (-0.65, -0.52)	0.59 (0.52, 0.65)	0.77 (0.72, 0.80)	0.04 (-0.05, 0.14)	7/7 (100%)

Spearman correlations with 95% bootstrap confidence intervals between Walking Period Distance DMOs and related/unrelated mobility constructs at the first visit assessment (T1). Numbers in Bold indicate either that coefficients met the expected correlations ($|r| \geq 0.50$ for convergent and $|r| < 0.20$ for divergent validity), or that $\geq 75\%$ of the DMO correlations met the expectations. The primary Walking Period Distance threshold definitions used in the main analyses are highlighted in bold and shaded green.

^a Digital mobility outcome

^b 6-minute walk test (6MinWT) distance

^c In the Acute phase, patients were not allowed to perform the 6MinWT, TUG and the 5 times chair rise test of the SPPB (therefore achieving a maximum of 8 points instead of 12) and were not asked about post-fracture LLFDI.

^d Short Physical Performance Battery (SPPB)

^e 4-meter supervised gait speed from the 4-meter walk test of the SPPB.

^f Timed up and Go

^g Late Life Function and Disability Index – Functional Component, total score.

^h Number of walking steps in walking bouts (average number per day).

ⁱ Blood Pressure




Figure A. Known-groups validity of Walking Period Distance DMOs across the four hip fracture recovery phase groups.




Figure B. Known-groups validity of Walking Period Distance DMOs across the four hip fracture recovery phase groups for participants recruited in Germany (n=229).




Figure C. Known-groups validity of Walking Period Distance DMOs across the four hip fracture recovery phase groups for participants recruited in Norway (n=237).




Figure D. Known-groups validity of Walking Period Distance DMOs across the four hip fracture recovery phase groups for participants recruited in France (n=39).

Table F. Real-world Walking Period Distances at the first visit (T1), stratified by recovery phase group.

DMO	Acute	Post-Acute	Extended	Long-Term
Distance in WBs >30s (m)				
Mean Distance in WBs >30s (m)	26 (22–32)	34 (28–45)	45 (32–67)	53 (40–86)
SD Distance in WBs >30s (m)	9 (5–16)	18 (10–35)	31 (14–70)	49 (19–108)
Median Distance in WBs >30s (m)	24 (20–28)	29 (25–34)	35 (27–42)	36 (30–46)
P95 Distance in WBs >30s (m)	43 (32–63)	64 (47–103)	102 (61–190)	146 (76–291)
Distance in Walking Cluster (m)				
Mean Distance in Walking Cluster (m)	78 (57–125)	105 (78–164)	193 (105–318)	269 (145–465)
SD Distance in Walking Cluster (m)	23 (1–69)	63 (25–134)	174 (52–325)	231 (78–520)
Median Distance in Walking Cluster (m)	70 (51–101)	83 (63–112)	114 (78–181)	144 (90–275)
P95 Distance in Walking Cluster (m)	112 (68–207)	208 (123–443)	549 (196–983)	738 (297–1492)

DMO values are shown as median (P25–P75) among participants with an occurrence of the Walking Period DMO. Recovery phase groups were stratified by the number of days from surgery to first visit: Acute (≤ 14 days), Post-Acute (15–42 days), Extended (43–182 days), Long-Term (183–365 days).